An Elizabeth Holmes documentary just did something almost no theatrical release manages anymore: it sold out. Not one screening, not a handful of festival premieres, but more than 2,000 shows across the United States in a single opening weekend. You Can See Everything, the A24-distributed film built around the Theranos founder, landed on 855 screens on October 16, 2026, and walked away with an estimated $15 million through Sunday, enough to land it at No. 2 at the North American box office.
For a nearly three-hour documentary about a biotech fraud case that most of the country first heard about a decade ago, that is a startling number. It is also, according to CNN, one of the biggest documentary releases in decades. The film comes from Nathan Fielder and Lance Oppenheim, two filmmakers with very different reputations, and its sudden commercial heat says as much about the tech industry’s current anxieties as it does about Holmes herself.
A $15 Million Weekend Nobody Priced In
Box office analysts rarely get surprised by limited releases, because the math is predictable: a few hundred screens, art-house audiences, modest grosses that either hold or fade fast. You Can See Everything broke that pattern. Opening on 855 screens, it generated an estimated $15 million from Friday through Sunday, according to The Hill, which first reported the 2,000-sold-out-shows figure that is now circulating across entertainment and business press.
That per-screen performance is the real story here. A24, the distributor behind the film, has a track record of turning specialty titles into cultural moments, but even by its own standards this is an outlier. The company described the opening as “one of the largest limited-release openings of the 21st century,” a characterization that, if it holds up through the coming weeks, puts the Holmes documentary in rarefied company for the genre.
Reports indicate a wide release is being planned for the following weekend, which would move the film from a curated set of theaters into mainstream multiplexes. If that expansion happens on schedule, the opening weekend numbers will likely look modest by comparison within a month. But right now, in the specialty film world, $15 million from under a thousand screens is the kind of number distributors build marketing campaigns around for years.
What “You Can See Everything” Actually Is
The film centers on Elizabeth Holmes, the founder and former chief executive of Theranos, the blood-testing startup that collapsed into one of Silicon Valley’s most notorious fraud cases. Unlike the dramatized retellings that have already covered this ground, You Can See Everything is a documentary, and according to The New York Times, it runs nearly three hours, a runtime that signals ambition beyond a straightforward true-crime recap.
What has generated the most conversation is Holmes’s own participation. According to reporting tied to the film’s promotional cycle, Holmes told the filmmakers: “I think this is the moment in time to capture this story before I’m gone.” She also told them directly, “I don’t have anything to hide,” a line that is likely to frame much of the critical conversation around the project given how central the question of transparency was to the original Theranos scandal.
Those statements matter for a reason that goes beyond the film itself. Holmes was convicted of fraud-related charges in January 2022 and has been serving a federal prison sentence since, a fact that is part of the public record independent of anything the documentary claims. Her decision to participate in a project filmed and released while that sentence is ongoing is itself part of what is driving audience curiosity, and it is a detail every major outlet covering the release has flagged.
Nathan Fielder and Lance Oppenheim: An Unusual Pairing
Nathan Fielder is not a conventional documentarian. He built his career on Comedy Central’s Nathan For You and HBO’s The Rehearsal, shows built around elaborate, often uncomfortable social experiments where the line between performance and reality blurs on purpose. Lance Oppenheim, his co-director, comes from a more traditional nonfiction background, known for intimate, slow-burn character studies. Putting those two sensibilities on the same Theranos project was always going to produce something stranger than a standard exposé.
Fielder has been candid about how disorienting the process was. “I’m struggling to this day to understand exactly what I experienced,” he said, describing his time around Holmes and her family during production, according to NBC News. He has also described the access itself as puzzling: “I don’t know why they want me there,” referring to Holmes and her partner Billy Evans inviting him into their home during filming. At a post-screening session at the Telluride Film Festival, he summed himself up more bluntly: “I’m a weird guy.”
That mix of unease and access is precisely what distinguishes this film from earlier Theranos content. Previous projects relied on reconstruction and outside reporting. This one appears to have gotten inside the room, which explains both the runtime and the intensity of the early reaction.
The Numbers, in Context
| Detail | Figure |
|---|---|
| Title | You Can See Everything |
| Subject | Elizabeth Holmes, founder of Theranos |
| Directors | Nathan Fielder and Lance Oppenheim |
| Distributor | A24 |
| Runtime | Nearly three hours |
| Theatrical release date | October 16, 2026 |
| Opening screens | 855 |
| Sold-out shows | More than 2,000 |
| Opening weekend gross (Fri-Sun) | Estimated $15 million |
| North America box office rank | No. 2 |
| Next step | Wide release reportedly planned for the following weekend |
Put those figures side by side and the pattern is clear: this is not a slow-building art film finding its audience over weeks. It is a title that opened at near-capacity across the majority of its screens on day one. That kind of demand curve usually belongs to franchise tentpoles, not three-hour documentaries about corporate fraud.
Why a Tech Documentary Is Outperforming Expectations
Part of the explanation is timing. The tech industry in 2026 is living through its own cycle of inflated valuations, breathless funding rounds, and executives making claims that outpace what their products can actually do. Theranos, which promised to run hundreds of blood tests from a single finger-prick sample and delivered neither the technology nor the honesty to back that promise, has become shorthand for exactly that failure mode. Watching Holmes revisit that story on camera, nearly a decade after Theranos dissolved, lands differently in a year when AI startups are making their own outsized claims to investors and the public.
That resonance is not incidental to the box office number. Audiences showing up for a documentary about one of the clearest cases of startup overreach on record, at a moment when “fake it until you make it” culture is under fresh scrutiny across AI, robotics, and crypto, suggests the film is being read as commentary on the present as much as a record of the past.
There is also the Fielder factor. His existing audience, built over a decade of formally inventive television, tends to follow him regardless of subject matter, and that fan base skews younger and more online than the typical documentary crowd. Combine that built-in audience with a subject matter that remains a fixture of true-crime podcasts, Reddit threads, and business-school case studies, and the opening weekend starts to look less like an anomaly and more like two large, overlapping audiences showing up for the same film at once.
Silicon Valley on Screen: How This Fits a Pattern
Holmes and Theranos are not new subjects for film and television. You Can See Everything arrives after a string of projects that mined the same collapse, each with a different format and a different distributor. The table below places it in that lineage.
| Title | Format | Platform/Distributor | Subject | Year |
|---|---|---|---|---|
| You Can See Everything | Theatrical documentary | A24 | Theranos / Elizabeth Holmes | 2026 |
| The Dropout | Limited series | Hulu | Theranos / Elizabeth Holmes | 2022 |
| The Inventor: Out for Blood in Silicon Valley | Documentary | HBO | Theranos / Elizabeth Holmes | 2019 |
| WeCrashed | Limited series | Apple TV+ | WeWork / Adam Neumann | 2022 |
| Super Pumped: The Battle for Uber | Limited series | Showtime | Uber / Travis Kalanick | 2022 |
What separates the new film from everything on that list is direct, on-camera participation from Holmes herself, filmed years after her conviction. Every earlier project worked from the outside, through reporting, court records, and dramatization. This one claims a level of access none of its predecessors had, which is likely the single biggest driver of both the ticket sales and the inevitable debate over whether that access amounts to a platform she has not earned.
A24’s Calculated Bet on Limited Release First
A24 did not stumble into this outcome. The studio has built its brand on a specific release strategy: open small, let scarcity and word of mouth build urgency, then expand once the cultural conversation is already underway. It is the same playbook that turned films like Hereditary and Everything Everywhere All at Once into events rather than just releases.
Applying that strategy to a three-hour documentary about a convicted fraudster was a genuine bet, because documentaries rarely generate the kind of must-see urgency that drives sold-out shows. The fact that it worked, and worked at this scale, validates the approach for A24 and gives the studio leverage heading into the wide release. Reports indicate that expansion is planned for the following weekend, which would let A24 ride the momentum of “sold out everywhere” headlines directly into a nationwide push, rather than having to build that urgency from scratch.
Market Impact: What This Means for Specialty Film
Specialty and art-house distribution has struggled for several years as streaming pulled mid-budget and documentary audiences away from theaters. An opening weekend of this size, for this kind of film, is a meaningful data point for an industry that has been searching for proof that theatrical documentaries can still draw a crowd.
If the wide release holds anywhere close to its per-screen pace, expect other studios to take a second look at true-crime and corporate-scandal documentaries as theatrical plays rather than straight-to-streaming products. That shift would matter for the broader film economy, where theatrical windows have been shrinking and documentaries in particular have been treated as streaming-first content almost by default. A $15 million limited-release weekend for a three-hour nonfiction film is the kind of number that reopens that conversation.
The Historical Weight of the Theranos Story
Theranos was once valued at roughly $9 billion, built on claims that its technology could run comprehensive diagnostic panels from a few drops of blood. That promise unraveled publicly starting in 2015, when investigative reporting exposed that the company’s core technology did not work as advertised. The fallout led to federal fraud charges, a high-profile trial, and Holmes’s conviction in January 2022. She has been serving a federal prison sentence since, a detail that remains central to how audiences and critics are approaching her decision to appear in this new film.
That history is also why the box office number carries weight beyond entertainment pages. Theranos has functioned for a decade as the default cautionary tale in venture capital and startup circles, cited constantly in conversations about founder accountability, investor due diligence, and the dangers of “fake it until you make it” culture. A documentary that reopens that story with the subject’s own participation, at a moment when AI valuations are drawing comparable skepticism, is landing in exactly the cultural moment that made its box office performance possible.
Competitive Comparison: Documentary vs. Dramatization
The format difference between You Can See Everything and its predecessors is worth dwelling on. The Dropout, the Hulu limited series, relied on scripted performance, with Amanda Seyfried portraying Holmes rather than Holmes portraying herself. The Inventor, HBO’s 2019 documentary, assembled its case almost entirely from archival footage, interviews with former employees, and investigative reporting, without direct access to Holmes.
Fielder and Oppenheim’s film breaks that mold by putting Holmes in front of the camera, in her own words, years after the legal process concluded. That is a fundamentally different proposition for audiences: instead of watching someone else’s interpretation of Holmes, viewers are watching Holmes attempt to narrate her own story in real time. Whether that counts as accountability or self-rehabilitation is likely to be the central critical debate around the film, but it is also precisely the hook that separates this release from everything that came before it.
What Happens at Wide Release
The expansion planned for the weekend following October 16 is the next real test. Limited releases routinely post strong per-screen numbers precisely because supply is artificially constrained; the harder question is whether that demand holds once the film is available on thousands of screens instead of 855. According to AOL, the $15 million opening is already being described as record-breaking for the category, which raises the bar for what the wide release needs to deliver to be read as a continued success rather than a natural plateau.
A24 will also be watching critical reception closely during this window. Reviews published since the Telluride Film Festival screening have been largely positive but divided on the ethics of giving Holmes a platform, according to The Independent. That tension is likely to shape word of mouth heading into the wide release more than any marketing push could.
Five Predictions for the Weeks Ahead
- The wide release will push the film’s cumulative gross well past its opening weekend total, though the per-screen average will likely drop sharply once it leaves specialty theaters for mainstream multiplexes.
- Expect renewed streaming and search interest in older Theranos content, including The Dropout and The Inventor, as viewers seek more context before or after watching the new film.
- Given A24’s track record with awards-season campaigns, a documentary-category push for You Can See Everything is likely once the qualifying window opens, particularly if critical reception stays strong through the wide release.
- The film’s commercial success will likely accelerate pitches for documentaries and dramatizations centered on other recent startup and corporate collapses, as studios look to replicate the demonstrated audience appetite.
- Debate over Holmes’s participation, and whether a convicted fraudster should be given a platform to narrate her own story, will intensify rather than fade as the film reaches a wider, less festival-savvy audience.
The Bigger Picture for Tech and Media
For a technology-focused audience, the real significance of this weekend is not the box office line item. It is the fact that a decade-old corporate fraud case still carries enough cultural charge to sell out 2,000 shows, at a moment when the tech industry is once again awash in ambitious claims that have not yet been tested against reality. Theranos has become a reference point that outlives its own news cycle, invoked every time a startup’s promises start outpacing its evidence.
That staying power is also a signal to media companies about audience appetite. A24 took a real risk putting a three-hour documentary into nearly a thousand theaters at once, and the bet paid off at a scale that is already being described, in A24’s own words, as one of the largest limited-release openings of the 21st century. Whether that momentum survives contact with a wide release, and whether it changes how studios treat tech-scandal stories going forward, will be the real test over the next several weeks.
Frequently Asked Questions
What is the Elizabeth Holmes documentary called?
It is titled You Can See Everything, distributed by A24 and directed by Nathan Fielder and Lance Oppenheim.
How much money did the film make on opening weekend?
A24’s limited release generated an estimated $15 million from Friday through Sunday, placing it at No. 2 at the North American box office for the weekend.
How many theaters is the film showing in?
It opened on 855 screens across the United States, with more than 2,000 individual showings reported as sold out that weekend.
Is Elizabeth Holmes actually in the documentary?
Yes. Unlike earlier dramatizations of the Theranos story, this documentary includes direct, on-camera participation from Holmes herself, filmed years after her 2022 fraud conviction.
Is the film getting a wide release?
Reports indicate A24 is planning a wide release for the weekend following the October 16, 2026 limited opening, which would move the film from specialty theaters into mainstream multiplexes nationwide.
How long is You Can See Everything?
The documentary runs nearly three hours, a notably long runtime for the genre that reflects the filmmakers’ ambition to go beyond a standard true-crime recap.
How does this compare to other Theranos-related projects?
It follows Hulu’s scripted series The Dropout (2022) and HBO’s documentary The Inventor: Out for Blood in Silicon Valley (2019), but it is the first major project to feature Holmes narrating her own story on camera.
Where is Elizabeth Holmes now?
Holmes was convicted on fraud-related charges in January 2022 and has been serving a federal prison sentence since, a fact widely reported independent of the documentary’s release.
